Original articleVirologyMaraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study
Virology
Under an Elsevier user license
open archive
Keywords
Antiretroviral therapy
human immunodeficiency virus
maraviroc
naive patients
nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen
Cited by (0)
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.